RU2013115128A - METHOD OF TREATMENT AND TACTICS FOR MANAGEMENT OF PREGNANT WOMEN WITH DRUG HEPATITIS - Google Patents
METHOD OF TREATMENT AND TACTICS FOR MANAGEMENT OF PREGNANT WOMEN WITH DRUG HEPATITIS Download PDFInfo
- Publication number
- RU2013115128A RU2013115128A RU2013115128/15A RU2013115128A RU2013115128A RU 2013115128 A RU2013115128 A RU 2013115128A RU 2013115128/15 A RU2013115128/15 A RU 2013115128/15A RU 2013115128 A RU2013115128 A RU 2013115128A RU 2013115128 A RU2013115128 A RU 2013115128A
- Authority
- RU
- Russia
- Prior art keywords
- day
- norms
- ursodeoxycholic acid
- transaminases
- ademethionine
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Способ лечения и тактика ведения беременных с лекарственным гепатитом, заключающийся в том, что после установления диагноза лекарственного гепатита проводят в 1-м триместре при бессимптомном повышении активности трансаминаз в пределах 3 норм и отсутствии противопоказаний перорально принимают растительные гепатопротекторы (карсил или гепабене) или эссенциальные фосфолипиды без витаминов (эслидин per os или эссен-циале форте Н в/в, per os) в стандартных дозах при отмене другой медикаментозной терапии, во 2-ом триместре при уровне сывороточных трансаминаз до 5 норм перорально принимают адеметионин 400 мг в/в N 7-10, затем per os 1600 мг/сут, курс лечения 1 месяц, при уровне сывороточных трансаминаз от 5 до 10 норм - адеметионин 800 мг в/в N 10 + урсодеоксихолевую кислоту 12 мг/кг/сут, при уровне сывороточных трансаминаз более 10 норм - адеметионин 800 мг/сут в/в + урсодеоксихолевая кислота 12 мг/кг/сут + преднизолон в/в 90 мг/сут, в 3-ем триместре при уровне сывороточных трансаминаз до 5 норм перорально принимают адеметионин 800 мг/сут в/в N10 + урсодеоксихолевую кислоту 13 мг/кг/сут, при уровне трансаминаз от 5 до 10 норм - адеметионин 800 мг/сут в/в + урсодеоксихолевую кислоту 13 мг/кг/сут + преднизолон в/в 90 мг/сут, при прогрессивном повышении уровня сывороточных трансаминаз свыше 10 норм на фоне терапии адеметионином 800 мг/сут в/в, урсодеоксихолевой кислотой 13 мг/кг/сут, преднизолоном в/в 120 мг/сут с ожиданием не более 3-х дней, а в послеродовом периоде терапию продолжают в полном объеме до нормализации «печеночных проб».A method of treatment and management tactics for pregnant women with drug hepatitis, which consists in the fact that, after a diagnosis of drug hepatitis is established, transaminases are performed in the 1st trimester with an asymptomatic increase in the range of 3 norms and there are no contraindications, plant hepatoprotectors (carlsil or hepatene) or essential phospholipids are orally administered without vitamins (eslidine per os or essential cyt forte H iv, per os) in standard doses with the cancellation of other drug therapy, in the 2nd trimester at a serum level up to 5 norms of ranaminaminase, odemethionine 400 mg IV 7-10 is taken orally, then 1600 mg / day per os, 1 month course of treatment, with serum transaminases from 5 to 10 norms, ademetionine 800 mg iv 10 N / ursodeoxycholic acid 12 mg / kg / day, with a serum transaminase level of more than 10 norms - ademethionine 800 mg / day iv + ursodeoxycholic acid 12 mg / kg / day + prednisolone iv 90 mg / day, in the 3rd trimester at serum transaminases up to 5 norms orally take ademethionine 800 mg / day iv N10 + ursodeoxycholic acid 13 mg / kg / day, with transaminases from 5 to 10 n orm - ademethionine 800 mg / day iv + ursodeoxycholic acid 13 mg / kg / day + prednisolone iv 90 mg / day, with a progressive increase in serum transaminases over 10 norms during therapy with ademethionine 800 mg / day iv with ursodeoxycholic acid 13 mg / kg / day, intravenous prednisone 120 mg / day with an expectation of no more than 3 days, and in the postpartum period, therapy is continued in full until the normalization of “liver tests”.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013115128/15A RU2537120C2 (en) | 2013-04-04 | 2013-04-04 | Method of treating and managing pregnant women with drug-induced hepatitis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013115128/15A RU2537120C2 (en) | 2013-04-04 | 2013-04-04 | Method of treating and managing pregnant women with drug-induced hepatitis |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2013115128A true RU2013115128A (en) | 2014-10-10 |
RU2537120C2 RU2537120C2 (en) | 2014-12-27 |
Family
ID=53287693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013115128/15A RU2537120C2 (en) | 2013-04-04 | 2013-04-04 | Method of treating and managing pregnant women with drug-induced hepatitis |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2537120C2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2655100C1 (en) * | 2017-03-21 | 2018-05-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Method of correction of experimental gestosis by ademetionine administration |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2736373C1 (en) * | 2020-03-24 | 2020-11-16 | федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации | Diagnostic method of individual indications for essentiale |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2381800C1 (en) * | 2008-09-29 | 2010-02-20 | Тимофей Георгиевич Кожока | Hepatoprotective and antihepatotoxic pharmaceutical composition and method of treating hepatic diseases that involves introduction of said composition |
-
2013
- 2013-04-04 RU RU2013115128/15A patent/RU2537120C2/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2655100C1 (en) * | 2017-03-21 | 2018-05-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Method of correction of experimental gestosis by ademetionine administration |
Also Published As
Publication number | Publication date |
---|---|
RU2537120C2 (en) | 2014-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2018114447A (en) | INTRODUCTION OF CFTER DUTERED AMPLIFIERS | |
RU2017134443A (en) | METHOD OF TREATMENT WITH USE OF TRADIPTANT | |
WO2015187087A3 (en) | Novel combinations for antigen based therapy | |
MY179870A (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
RU2013115128A (en) | METHOD OF TREATMENT AND TACTICS FOR MANAGEMENT OF PREGNANT WOMEN WITH DRUG HEPATITIS | |
AR075345A1 (en) | TREATMENT WITH DELAYED RELEASE GLUCOCORTICOIDS OF Rheumatoid ARTHRITIS THAT IMPROVES SIGNS AND SYMPTOMS, SHOWS TOTAL OR COMPLETE CLINICAL RESPONSE AND PREVENTS DAMAGE TO ARTICULATIONS | |
Furutama et al. | Recurrent high-dose intravenous methylprednisolone succinate pulse therapy-induced hepatopathy in a patient with multiple sclerosis | |
JP2016514142A5 (en) | ||
FI3137094T3 (en) | Treatment and prevention of alzheimer's disease (ad) | |
Maruyama | Scleroderma renal crisis with thrombotic microangiopathy: 2 case reports | |
MD4177B1 (en) | Method for vaccination against hepatitis B of persons with immunodeficiency | |
Luke | Ipilimumab/sargramostim | |
LIU et al. | Anti-fatigue effects of N-benzylhexadecanamide and Maca extract in mice | |
JP2016514143A5 (en) | ||
Unel et al. | The acute effects of chlorogenic acid in cisplatin-induced peripheral neuropathy | |
Lammert | Corticosteroids/ipilimumab | |
Mehta | Ipilimumab/nivolumab | |
EA201692107A1 (en) | TREATMENT SCHEME TYACUMICINE CONNECTION | |
RU2020143245A (en) | 19-NOR С3,3-SUBSTITUTED С21-N-PYRAZOLYL STEROIDE AND METHODS FOR ITS APPLICATION | |
Grosen | Serum sickness-like reaction during pregnancy: case report | |
Yang | Methotrexate/prednisolone | |
Todorov | Drug fever: case report | |
UA92642U (en) | Method for correcting hyperhomocysteine-induced endothelial dysfunction, predominantly in pregnant patients | |
Xu | Methylprednisolone/prednisone | |
Wallace et al. | Adalimumab Therapy Achieves Clinical Remission and Response at Week 26 in Chinese Patients With Crohn's Disease: 1874 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150405 |